|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Written by Jeffrey Neal Johnson. Publication Date: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In investing, stability is a prized commodity. Few companies embody it better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more notable.
SpaceX is preparing an offering that could raise $50 billion in a single day - and Bloomberg reports it's already forcing other companies to delay their own IPOs.
Citigroup just joined the underwriting team. But the real positioning isn't in the IPO itself - it's in the one chokepoint supplier that SpaceX's $1.75 trillion empire depends on to stay operational. See what insiders are buying before the SpaceX IPO hits
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the final trading days of March. This sharp drop has prompted questions about whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a potential disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market’s pessimism is justified or whether a meaningful value opportunity has emerged. Separating the Signal From the NoiseAbbott’s recent decline reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% decline in organic sales for this division, driven largely by market-share losses in its U.S. pediatric business and pricing dynamics that pressured volumes. Management has acknowledged the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 aimed at reigniting volume growth, with a return to growth expected in the second half of the year. The second factor is external and broader in scope: a market-wide rotation of capital. In periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That broad trend has weighed on many fundamentally sound healthcare companies, including Abbott, pressuring share prices for reasons unrelated to company-level fundamentals or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition business navigates a near-term recovery, Abbott’s core remains robust, led by its largest and most profitable division: Medical Devices. That segment posted 10.4% organic growth in the most recent quarter and helps offset the isolated weakness in nutrition. The company’s true strength is most evident in these high-performing areas.
Medical Devices: The Medical Devices division is gaining momentum, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a major growth driver. This product line, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and remains central to Abbott’s growth trajectory. Cardiovascular Leadership: Abbott is a strong player in cardiovascular health. Its Electrophysiology business grew in double digits, while Structural Heart posted robust organic growth of 8.7%. This strength stems from a portfolio of best-in-class products—such as MitraClip and TriClip—and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also pursuing strategic expansion to secure future growth, notably through its announced acquisition of Exact Sciences. Exact Sciences, best known for its non-invasive colon cancer test Cologuard, will give Abbott a meaningful foothold in the rapidly expanding market for cancer diagnostics. The deal would immediately position Abbott as a leader in a multi-billion-dollar, high-growth diagnostics market and add a new vertical expected to contribute materially to revenue over time. Analysts broadly share this constructive view. Wall Street maintains a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47—implying potential upside of more than 30% from current levels. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a key attraction. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record underscores a deep commitment to returning capital to shareholders across market cycles. The recent share-price decline also benefits new investors by boosting yield. At current prices, Abbott offers a dividend yield of about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The payout ratio is roughly 68% of earnings, and the dividend represents about 37% of cash flow—indicating Abbott generates more than enough cash to cover payments and retain flexibility for future increases. A Disconnect Between Price and ValueCurrent market sentiment toward Abbott appears disconnected from the company’s operational reality. Temporary headwinds in a single division, combined with broader market rotation, have depressed the stock price even as Abbott’s fundamental growth drivers accelerate. Its dominant Medical Devices franchise continues to deliver, the dividend remains secure, and catalysts such as the Exact Sciences acquisition could add meaningful growth. For investors with a long-term horizon, the current valuation suggests a notable gap between market price and intrinsic value—an opportunity worth considering. |
